Tim Kümmerle
YOU?
Author Swipe
View article: Switching to a NRTI-free 2 drug regimen (2DR) –a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes
Switching to a NRTI-free 2 drug regimen (2DR) –a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes Open
Background/Aims: Switching from a three-drug regimen (3DR: boosted darunavir [bDRV] and two nucleoside reverse transcriptase inhibitors [NRTIs]) to a two-drug regimen (2DR: bDRV and dolutegravir [DTG]) demonstrated non-inferiority with reg…
View article: Predictors of serofast state after treatment for early syphilis in HIV‐infected patients
Predictors of serofast state after treatment for early syphilis in HIV‐infected patients Open
Objectives Non‐treponemal serological tests are used to monitor treatment response during syphilis infection. Syphilis‐ and HIV‐coinfected patients may experience incomplete resolution in non‐treponemal titres, which is referred to as the …
View article: Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study
Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study Open
Background Dolutegravir (DTG) and boosted darunavir (bDRV) are potent antiretrovirals with a high resistance barrier and might be valuable switch options for people with HIV (PWH). Methods DUALIS, a randomized, open-label, phase 3b, noninf…
View article: To prescribe, or not to prescribe: decision making in HIV‐1 post‐exposure prophylaxis
To prescribe, or not to prescribe: decision making in HIV‐1 post‐exposure prophylaxis Open
Objectives We investigated the trend in usage of post‐exposure prophylaxis ( PEP ) after HIV ‐1 risk exposure and evaluated PEP prescription decision making of physicians according to guidelines. Methods All PEP consultations from January …
View article: Pharmacokinetics of once-daily dolutegravir and ritonavir-boosted darunavir in HIV patients: the DUALIS study
Pharmacokinetics of once-daily dolutegravir and ritonavir-boosted darunavir in HIV patients: the DUALIS study Open
aetiological bacteria in infected bones. 6 Furthermore, ceftolozane/ tazobactam, like b-lactams, has a good safety profile and low risk of drug-drug interaction, thereby enabling prolonged therapy. 7iven its stability against the most comm…
View article: Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy Open
Among serodifferent heterosexual and MSM couples in which the HIV-positive partner was using suppressive ART and who reported condomless sex, during median follow-up of 1.3 years per couple, there were no documented cases of within-couple …
View article: <scp>PEPD</scp>ar: A randomized prospective noninferiority study of ritonavir‐boosted darunavir for HIV post‐exposure prophylaxis
<span>PEPD</span>ar: A randomized prospective noninferiority study of ritonavir‐boosted darunavir for HIV post‐exposure prophylaxis Open
Objectives PEPD ar compared the tolerability and safety of ritonavir‐boosted darunavir ( DRV /r)‐based post‐exposure prophylaxis ( PEP ) with the tolerability and safety of standard of care ( SOC ). The primary endpoint was the early disco…
View article: How successful is influenza vaccination in HIV infected patients? Results from an influenza A(H1N1)pdm09 vaccine study
How successful is influenza vaccination in HIV infected patients? Results from an influenza A(H1N1)pdm09 vaccine study Open
To determine immune response after single vaccination with AS03-adjuvanted pandemic H1N1 vaccine in HIV-infected patients. Individuals living with human immunodeficiency virus (HIV) are at risk with influenza due to hyporesponsiveness to i…